Literature DB >> 7590661

Abnormal expression of PDC-E2 on the apical surface of biliary epithelial cells in patients with antimitochondrial antibody-negative primary biliary cirrhosis.

K Tsuneyama1, J Van De Water, D Van Thiel, R Coppel, B Ruebner, Y Nakanuma, E R Dickson, M E Gershwin.   

Abstract

The presence of antimitochondrial antibodies (AMA) is a major criterion for the diagnosis of primary biliary cirrhosis (PBC). Although it is not clear that AMA are involved in the pathogenesis of the disease, the study of these autoantibodies has enabled much information to be accumulated about the specificity of this response. The autoantigens have been identified as components of a functionally related enzyme family, the 2-oxo-acid-dehydrogenase complex. Within this complex, pyruvate dehydrogenase E2 subunit (PDC-E2) has been determined to be the immunodominant autoantigen. Using a panel of mouse monoclonal antibodies and human combinatorial autoantibodies, it has been demonstrated that patients with PBC, but not controls, have an abnormal expression of either PDC-E2 or a cross-reacting molecule in the apical region of biliary epithelium. Others have shown a similar reaction using rabbit sera directed to PDC-E2. Our previous studies have concentrated on AMA-positive patients. In this study, the presence of PDC-E2, class II, immunoglobulin (Ig) A, and B7/BB1 in the bile duct epithelial cells of AMA-positive as well as AMA-negative patients is addressed. Most patients with AMA-negative PBC (seven of nine) react in a fashion similar to AMA-positive patients with intense staining of the apical region of the bile duct epithelial cells of "PDC-E2," increased IgA expression, and little major histocompatibility complex (MHC) class II staining in the early-stage patients. Interestingly, the two AMA-negative patients that did not express PDC-E2 on the apical side of their biliary epithelium had anticentromere antibodies and Sjögren's syndrome.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7590661

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  10 in total

Review 1.  Autoimmune hepatitis and its variant syndromes.

Authors:  Z Ben-Ari; A J Czaja
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

Review 2.  Variant forms of autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

3.  Transgenic mice aberrantly expressing pyruvate dehydrogenase complex E2 component on biliary epithelial cells do not show primary biliary cirrhosis.

Authors:  K Inamura; H Tsuji; Y Nakamoto; M Suzuki; S Kaneko
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

4.  Presence of disease specific autoantibodies against liver sinusoidal cells in primary biliary cirrhosis.

Authors:  Ourania Sfakianaki; Maria Tzardi; Argyro Voumvouraki; Aikaterini Afgoustaki; Meri Koulentaki; Elias Kouroumalis
Journal:  World J Hepatol       Date:  2013-10-27

5.  Hepatic dysfunction in hyperthyroidism.

Authors:  Saro Khemichian; Tse-Ling Fong
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-05

6.  Autoimmune cholangitis.

Authors:  J Heathcote
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

Review 7.  Overlap syndromes among autoimmune liver diseases.

Authors:  Christian Rust; Ulrich Beuers
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

Review 8.  Primary biliary cirrhosis is a generalized autoimmune epithelitis.

Authors:  Jun Gao; Liang Qiao; Bingyuan Wang
Journal:  Int J Mol Sci       Date:  2015-03-20       Impact factor: 5.923

9.  Serum Metabolomics Analysis Reveals a Distinct Metabolic Profile of Patients with Primary Biliary Cholangitis.

Authors:  Juan Hao; Tao Yang; Yang Zhou; Guo-Yuan Gao; Feng Xing; Yuan Peng; Yan-Yan Tao; Cheng-Hai Liu
Journal:  Sci Rep       Date:  2017-04-11       Impact factor: 4.379

Review 10.  Antigen-Specific Immunotherapy for Treatment of Autoimmune Liver Diseases.

Authors:  Naomi Richardson; Sky T H Ng; David C Wraith
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.